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SUMMARY
NMDA receptors (NMDARs) play subunit-specific roles in synaptic function and are implicated in 
neuropsychiatric and neurodegenerative disorders. However, the in vivo consequences and 
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therapeutic potential of pharmacologically enhancing NMDAR function via allosteric modulation 
are largely un-known. We examine the in vivo effects of GNE-0723, a positive allosteric 
modulator of GluN2A-subunit-containing NMDARs, on brain network and cognitive functions in 
mouse models of Dravet syndrome (DS) and Alzheimer’s disease (AD). GNE-0723 use 
dependently potentiates synaptic NMDA receptor currents and reduces brain oscillation power 
with a predominant effect on low-frequency (12–20 Hz) oscillations. Interestingly, DS and AD 
mouse models display aberrant low-frequency oscillatory power that is tightly correlated with 
network hypersynchrony. GNE-0723 treatment reduces aberrant low-frequency oscillations and 
epileptiform discharges and improves cognitive functions in DS and AD mouse models. GluN2A-
subunit-containing NMDAR enhancers may have therapeutic benefits in brain disorders with 
network hypersynchrony and cognitive impairments.
Graphical Abstract
In Brief
Hanson et al. examine the therapeutic effects of enhancing GluN2A-subunit-containing NMDAR 
function in Dravet syndrome and Alzheimer’s disease mice. GNE-0723 treatment reduces aberrant 
low-frequency oscillations and epileptiform discharges and improves cognitive functions in both 
disease models. GluN2A NMDAR enhancers may benefit brain disorders with network 
hypersynchrony and cognitive impairments.
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INTRODUCTION
NMDA receptors (NMDARs) are ionotropic glutamate receptors that play key roles in 
synaptic plasticity and are implicated in neurological disorders (Paoletti et al., 2013; 
Traynelis et al., 2010). NMDARs are tetrameric; composed of GluN1, GluN2A-D, and 
GluN3A-B subunits; and typically consist of two GluN1 subunits and two GluN2 subunits in 
adult animals (Kehoe et al., 2013; Paoletti et al., 2013; Traynelis et al., 2010). In pyramidal 
cells, synaptic NMDARs typically contain GluN2A subunits, display faster kinetics, and 
mediate long-term synaptic plasticity, whereas extrasynaptic NMDARs typically lack 
GluN2A subunits, contain mainly GluN2B subunits, and display slower kinetics.
Until recently, insight into the in vivo function of NMDARs has come mostly from 
pharmacological modulation of NMDARs with limited synaptic and NMDAR-subunit 
selectivity, mainly using antagonists, such as ketamine, memantine, or MK-801. Treatment 
with these NMDAR blockers induces a schizophrenia-like syndrome in humans (Javitt and 
Zukin, 1991; Krystal et al., 1994; Rivolta et al., 2015) and rodents (Zajaczkowski et al., 
2003), including locomotor hyperactivity, aberrant electroencephalogram (EEG) oscillatory 
activity, and cognitive impairments. Although NMDARs are found on inhibitory and 
excitatory neurons, it has been proposed that the underlying mechanism of the in vivo effects 
of NMDAR blockers involves reduction of inhibitory interneuron activation, leading to dis-
inhibition of pyramidal cells and increased cortical excitability (Gonzalez-Burgos and 
Lewis, 2012; Miller et al., 2016; Picard et al., 2019; Sapkota et al., 2016). Consistently, 
inhibition of NMDARs by MK-801 causes a reduction in the firing rate of fast-spiking 
interneurons and a subsequent increase in pyramidal cell firing rates in awake rats 
(Homayoun and Moghaddam, 2007). The preferential impact of NMDAR antagonists on 
fast-spiking interneurons in vivo is thought to result from greater basal NMDAR activation 
in interneurons due to their higher rate of firing and more depolarized membrane potential, 
which relieves pore block by Mg2+ (Cohen et al., 2015). A preferential effect of NMDAR 
antagonists on the parvalbumin (PV) interneuron-enriched GluN2D subunit under 
physiological conditions could also contribute (Kotermanski and Johnson, 2009; Perszyk et 
al., 2016). Notably, GluN2D knockout mice or mice with global or PV interneuron-specific 
knockout of GluN2A lack ketamine-induced, schizophrenia-related phenotypes, including 
hyperlocomotion and excessive gamma oscillatory activity (Picard et al., 2019; Sapkota et 
al., 2016).
Although the functional roles of synaptic and extrasynaptic NMDARs in health and disease 
are not fully understood, extrasynaptic GluN2B-containing NMDARs may mediate 
neurotoxicity in Alzheimer’s disease (AD) pathogenesis and other brain disorders (Hu et al., 
2009; Li et al., 2011; Mony et al., 2009; Snyder et al., 2005; Um et al., 2012). Interestingly, 
the NMDAR antagonist memantine, which is used to treat moderate-to-severe AD, might 
exert neuroprotection by blocking aberrant activation of extrasynaptic GluN2B-containing 
NMDARs but may also block synaptic NMDAR function (Hardingham et al., 2002; Lipton, 
2005; Papadia and Hardingham, 2007; Xia et al., 2010; Zhou and Sheng, 2013). Therefore, 
GluN2A-containing NMDARs represent an attractive and complementary target for 
selectively enhancing synaptic NMDAR function while avoiding extrasynaptic 
neurotoxicity.
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Toward this goal, selective positive allosteric modulators (PAMs) of GluN2A-subunit-
containing NMDARs (GluN2A PAMs) have been identified (Hackos et al., 2016). Unlike 
agonists, GluN2A PAM compounds enhance synaptic NMDAR currents only when and 
where NMDARs are naturally activated by synaptic glutamate release and therefore 
selectively enhance endogenous NMDAR activity. Given that NMDAR antagonists 
predominantly increase network hypersynchrony in vivo, drugs that enhance the function of 
synaptic NMDARs may potentially be beneficial in suppressing pathological 
hypersynchrony. However, in contrast to the extensive data on NMDAR antagonists, little is 
known about the in vivo consequences of pharmacologically enhancing NMDAR function or 
the therapeutic potential of this approach.
Reduced interneuron function and pathological network hypersynchrony have been 
implicated in neuropsychiatric and neurodegenerative disorders, including schizophrenia, 
Dravet syndrome (DS), and AD. DS is a genetic epileptic encephalopathy often caused by de 
novo nonsense mutations in the SCN1A gene, resulting in haploinsufficiency of the voltage-
gated sodium channel Nav1.1 (Catterall et al., 2010). Nav1.1 is predominantly expressed in 
medial ganglionic eminence (MGE)-derived inhibitory interneurons, which have 
proportionally higher Nav1.1 levels relative to other Nav subunits (Saunders et al., 2018). 
Fast-spiking action potential activity is also associated with higher levels of Nav1.1 and 
lower levels of Nav1.2 (Saunders et al., 2018). Nav1.1-deficient mice have selective 
reductions in both PV and somatostatin interneuron action potential firing rates that are 
thought to contribute to the epileptic phenotypes (Catterall et al., 2010; Martinez-Losa et al., 
2018; Ogiwara et al., 2007; Rubinstein et al., 2015; Tai et al., 2014; Yamakawa, 2009; Yu et 
al., 2006). Nav1.1 levels are also reduced in mouse models of AD, including J20, APP/PS1, 
and TgCRND8 mice, and in humans with AD (Hamm et al., 2017; Hu et al., 2017; Verret et 
al., 2012). Beta-secretase (BACE)-1-dependent Nav1.1 hypofunction has also been 
suggested in Tg2576 and BACE1 transgenic mice (Corbett et al., 2013; Kim et al., 2007). 
Thus, interneuron hypofunction may contribute to network hypersynchrony and oscillatory 
alterations in mouse models of DS and AD.
Previously developed GluN2A PAMs, including GNE-6901 and GNE-8324 (Hackos et al., 
2016), had unfavorable pharmacokinetic (PK) properties that prevented evaluation of their 
potential therapeutic effects in relevant disease models in vivo. In this study, we use 
GNE-0723, a related GluN2A PAM with high potency and favorable PK properties (Volgraf 
et al., 2016), to explore the functional consequences of enhancing synaptic NMDAR 
function in vivo. High GNE-0723 doses caused behavioral changes in wild-type, but not in 
GluN2A knockout (KO), mice that were contrary to the effects of NMDAR antagonists, 
suggesting that GNE-0723 specifically enhances GluN2A-containing NMDAR function in 
vivo. We proceeded to test the therapeutic effects of GNE-0723 treatment in DS and AD 
mouse models, which exhibit altered oscillatory activity, network hypersynchrony, and 
behavioral alterations. Treatment with a low dose of GNE-0723 reduced aberrant low-
frequency (12–20 Hz) oscillatory activity, network hypersynchrony, and cognitive 
impairment in DS and AD mouse models. Our results demonstrate the potential therapeutic 
benefit of enhancing GluN2A-containing NMDARs in brain disorders with impaired 
inhibitory function, network hypersynchrony, and cognitive impairments, including DS and 
AD.
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RESULTS
GNE-0723 Is a GluN2A PAM with Appropriate Properties for In vivo Use
GNE-0723 potentiates recombinant GluN2A-containing NMDARs with an EC50 of 
approximately 20 nM and at least 250-fold selectivity against GluN2B-containing NMDARs 
and AMPARs in cell-based assays (Hackos et al., 2016). Whole-cell recordings at room 
temperature (RT) from cell lines expressing GluN2A-containing NMDARs showed that 1 
μM GNE-0723 enhanced the peak current and slowed the current deactivation in response to 
brief pulses of glutamate (Glu) (Figures 1A, 1B, and S1). GNE-0723 at 1 μM enhanced 
NMDAR currents evoked by a wide range of Glu concentrations (0.03–100 μM), which was 
reflected in a significant lowering of the Glu EC50 in the presence of GNE-0723 (Figures 1A 
and 1C). GNE-0723 potentiation of NMDAR currents was equally robust when tested at RT 
or 37°C (Figure S1).
Single oral dosing of 1, 3, and 10 mg/kg of GNE-0723 in wild-type mice resulted in dose-
linear plasma concentrations with respective calculated unbound Cmax concentrations of 5, 
12, and 46 nM (Figure 1D). Low clearance was observed for GNE-0723, with stable plasma 
and brain levels maintained for at least 24 h following dosing with 3 mg/kg GNE-0723 
(Figures 1D and 1E). GNE-0723 also showed excellent brain penetration, reflecting a lack of 
active efflux with similar unbound plasma and brain GNE-0723 concentrations during the 24 
h post-dose (Figure 1E). In contrast to GNE-0723, previously reported GluN2A PAMs, 
GNE-6901 and GNE-8324 (Hackos et al., 2016), were rapidly cleared and did not achieve 
physiologically relevant concentrations after oral dosing (Volgraf et al., 2016).
We next tested GNE-0723 under more physiologically relevant conditions using 
piezoelectric solution switching to allow repeated synaptic-like Glu applications (5 ms; 100 
μM). Under these conditions, the prominent effect of 30 nM GNE-0723 was to slow 
deactivation of the NDMAR current rather than enhance peak current (Figure 1F). Repeated 
Glu applications at 30-s or 90-s intervals in the presence of GNE-0723 resulted in use-
dependent potentiation of GluN2A-containing NMDARs currents (Figures 1G and 1H), 
suggesting active synapses in vivo may potentially undergo a similar use-dependent 
potentiation.
GNE-0723 Potentiates NMDAR EPSCs in Excitatory and Inhibitory Neurons Ex Vivo
We previously found that distinct GluN2A PAMs, GNE-6901 and GNE-8324, greatly vary 
in their ability to potentiate NMDARs currents at synapses (Hackos et al., 2016). Therefore, 
we tested the ability of GNE-0723 to potentiate evoked NMDAR excitatory postsynaptic 
currents (EPSCs) in cortical pyramidal neurons and inhibitory interneurons in brain slices 
from adult mice. GNE-0723 application at 0.3 and 1.0 μM robustly increased the peak 
(196% ± 68%; p < 0.05 and 243% ± 62%; p < 0.05, respectively), area (289% ± 112%; p < 
0.05 and 419% ± 147%; p < 0.05), and decay time (177% ± 28%; p < 0.001 and 244% 
± 80%; p < 0.05) of evoked NMDAR EPSCs in pyramidal neurons (Figures 2A, 2C, and 
2E), demonstrating the ability of GNE-0723 to potentiate native synaptic NMDARs in brain 
slices. Next, we tested for GNE-0723 effects on evoked NMDAR EPSCs recorded from PV-
positive interneurons that were identified using a fluorescent reporter driven by PV-cre 
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recombinase expression. Similar to pyramidal neurons, 0.3 and 1.0 mM GNE-0723 also 
showed a robust potentiation of the peak (152% ± 32%; p = 0.06 and 155% ± 36%; p < 
0.05), area (194% ± 52%; p < 0.05 and 275% ± 77%; p < 0.05), and decay time (124% 
± 11%; p < 0.05 and 208% ± 36%; p < 0.001) of evoked NMDAR EPSCs in PV-positive 
interneurons (Figures 2B, 2D, and 2F). Consistent with use-dependent potentiation of 
recombinant NMDARs by GNE-0723 (Figures 1G, 1H, and S1), there was a relatively slow 
onset of GNE-0723 potentiation in both pyramidal neurons and PV interneurons in brain 
slices during stimulation with a 30-s inter-stimulus interval. Because synaptic NMDARs on 
both excitatory and inhibitory neurons could be robustly potentiated under these ex vivo 
conditions, it is reasonable to speculate that both excitatory and inhibitory cells could 
contribute to the in vivo effects of GNE-0723.
GNE-0723-Induced Behavioral Changes Depend on GluN2A-Containing NMDARs
Because NMDAR antagonists cause hyperlocomotion in mice (Zajaczkowski et al., 2003), 
we reasoned that enhancing GluN2A-containing NMDAR function with GNE-0723 may 
cause hypoactivity. As previously described (Dravid et al., 2007), we observed dose-
dependent increases in locomotor activity by (+)-MK-801 in wild-type (WT) mice (Figure 
S2A). (+)-MK-801 caused hyperactivity at a dose at which the less-potent enantiomer (–)-
MK-801 had no effects (Figure S2B), indicating that these behavioral effects were mediated 
by NMDAR blockade. In contrast, high doses of GNE-0723 suppressed ambulatory 
locomotor activity (10 mg/kg) and rearings (6 and 10 mg/kg) in WT mice, whereas the lower 
3-mg/kg dose had no effects on ambulatory locomotor activity and a trend toward reduced 
rearings (Figures 3A and 3B).
To determine whether GNE-0723-induced behavioral effects are mediated by GluN2A-
containing NMDARs, we next examined the locomotor effects of acute GNE-0723 treatment 
in GluN2A knockout (GluN2AKO) mice. As previously observed, and consistent with 
NMDA hypofunction (Boyce-Rustay and Holmes, 2006), GluN2AKO mice exhibited 
increased basal ambulatory locomotor activity compared to WT mice (Figures S2C, 3A, and 
3C). In contrast to WT mice, GNE-0723 at 3, 6, and 10 mg/kg did not alter ambulatory 
locomotor activity or rearings in GluN2A KO mice (Figures 3C and 3D). These results 
indicate that GNE-0723-induced behavioral changes are mediated by GluN2A-containing 
NMDARs.
GluN2A-Containing NMDARs Modulate Network Oscillatory Activity in Behaving Mice
Changes in brain network oscillatory activity correlate with psychiatric symptoms, 
epileptiform activity, and cognitive performance in psychiatric and neurological disorders 
(Palop and Mucke, 2016). To examine the impact of GluN2A-containing NMDARs 
modulation on brain function and its potential therapeutic profile, we first determined the 
effects of GNE-0723 on brain network oscillations during active wake and NREM by EEG 
recordings and compared its oscillatory profile to the pro-psychotic NMDAR blocker (+)-
MK-801. At the lower 3-mg/kg dose, GNE-0723 selectivity reduced the power of low-
frequency oscillations within the 12- to 20-Hz band (alpha and low beta), but not within the 
delta (0.5–6 Hz), theta (6–10 Hz), or gamma (30–80 Hz) bands, during active wake and 
NREM (Figures 3E, 3F, and S3A). At the higher dose (10 mg/kg), GNE-0723 reduced the 
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power across frequency bands and brain states, including delta, theta, alpha, and gamma 
(Figures 3E, 3F, and S3A). Contrary to GNE-0723, (+)-MK-801 prominently increased the 
power of low-frequency oscillations, including the delta (0.5–6 Hz) band (Figure S3B). 
Thus, enhancing GluN2A-containing NMDARs by low doses of GNE-0723 predominantly 
suppresses low-frequency (12–20 Hz) oscillations without altering gamma oscillations or 
locomotor activity, whereas blocking NMDAR function predominantly increased low-
frequency oscillatory power and induced hyperactivity.
Pathological Network Hypersynchronization Emerges during Low-Frequency Oscillatory 
Activity in DS and AD Mouse Models
Oscillatory rhythms reflect behavioral states and strongly modulate network synchrony in 
health and disease (Palop and Mucke, 2016). Resting brain states with increased low-
frequency (e.g., 12–20 Hz) oscillatory power are characterized by large-amplitude EEG 
signals and a high degree of network synchrony between adjacent brain regions (Palop and 
Mucke, 2016). Because such hypersynchronous brain states are associated with epileptic 
activity, GluN2A PAM treatment could potentially be beneficial in epileptic brains by 
reducing low-frequency (12–20 Hz) oscillatory power. Thus, we characterized Scn1a-KI 
mice that carry a heterozygous loss-of-function knockin (KI) mutation in the voltage-gated 
sodium channel Scn1a gene (Scn1a-KI mice), which results in Nav1.1 haploinsufficiency 
and DS (Ogiwara et al., 2007; Yamakawa, 2009), and the J20 mouse model of AD, which 
overexpresses human amyloid precursor protein with the Swedish and Indiana familial AD 
mutations (Mucke et al., 2000). Scn1a-KI and J20 mice have interneuron deficits, 
spontaneous epileptiform discharges (EDs), and cognitive deficits (Martinez-Losa et al., 
2018; Ogiwara et al., 2007; Palop et al., 2007; Palop and Mucke, 2016; Verret et al., 2012).
To determine whether pathological network hypersynchronization is associated with 
oscillatory rhythms in Scn1a-KI and J20 mice, we monitored spontaneous EDs, oscillatory 
rhythms, and locomotor activity by intracranial EEG recordings while mice explored a novel 
environment. Consistent with our previous findings (Martinez-Losa et al., 2018), Scn1a-KI 
and J20 mice had spontaneous EDs (Figure 4A, top), which were much more frequent 
during periods of low locomotor activity and almost absent during high locomotor activity 
(Figure 4A, bottom). Oscillatory frequency analyses revealed that the power of gamma-(30–
80 Hz) and low-frequency (12–20 Hz) oscillations were strongly anticorrelated and 
associated with high and low locomotor activity, respectively, in Scn1a-KI and J20 mice 
(Figures 4A and 4B). Linear regression analysis showed that EDs were indeed strongly 
associated with increased 12- to 20-Hz power and decreased 30- to 80-Hz power in DS and 
J20 mice (Figures 4C and 4D). These results indicate that aberrant network 
hypersynchronization is tightly correlated with oscillatory rhythms and behavioral states in 
Scn1a-KI and J20 mice.
Enhancing GluN2A-Containing NMDARs Ameliorates Pathological Network 
Hypersynchrony in Scn1a-KI and J20 Mice
Because increased low-frequency (12–20 Hz) oscillatory power was strongly associated with 
network hypersynchronization in Scn1a-KI and J20 mice (Figure 4) and in humans with 
epilepsy (Boly et al., 2017; Vaudano et al., 2017; Matsumoto et al., 2013; Palop and Mucke, 
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2016), we wondered whether the suppressive effects of GNE-0723 on low-frequency 
oscillations could ameliorate the network hypersynchronization seen in these mouse models. 
To test this hypothesis, we recorded two 50-min EEG sessions in Scn1a-KI and J20 mice 
before (pretreatment session) and 30 min after administration of vehicle or 3 mg/kg 
GNE-0723, a dose that significantly reduced 12- to 20-Hz power with minimal or no effects 
on locomotor activity (Figure 3).
As expected, 12- to 20-Hz power increased during the two EEG sessions as mice habituated 
to the arena and their exploratory activity decreased (Figures 5A and S4A). Scn1a-KI mice 
showed elevated 12- to 20-Hz power relative to WT controls during the baseline session, 
reflecting the aberrant network synchrony in this model. GNE-0723 significantly reduced 
12- to 20-Hz power for both WT and Scn1a-KI mice relative to vehicle-treated controls 
(Figures 5A and 5B) without affecting locomotor activity (Figure S4A) or gamma 
oscillatory power (30–80 Hz; Figure S4B). Because increased 12- to 20-Hz power is 
associated with EDs in Scn1a-KI mice (Figure 4), we next examined whether the 
suppressive effects of GNE-0723 on 12- to 20-Hz power were also associated with reduced 
rates of EDs. Indeed, we found that 3 mg/kg GNE-0723 significantly reduced the frequency 
of EDs in Scn1a-KI mice when compared to vehicle (Figures 5C–5E), whereas no 
differences on EDs were observed during the baseline session. Consistent with our initial 
observations (Figure 4), the power of 12–20 Hz negatively correlated with locomotor 
activity (Figure 5F) and positively correlated with EDs (Figure 5G) in Scn1a-KI mice, 
indicating a clear relationship between behavioral state and aberrant network 
hypersynchrony in this mouse model. Interestingly, GNE-0723 did not alter the tight 
correlation between 12- to 20-Hz power and ED rate (Figure 5G) but instead reduced 12- to 
20-Hz power across locomotor activity levels (Figure 5F). These results indicate that 12- to 
20-Hz power and EDs are tightly linked in Scn1a-KI mice and that GNE-0723 may reduce 
EDs by suppressing pro-hypersynchronous low-frequency oscillations.
Because aberrant network hypersynchronization was also tightly linked to oscillatory 
activity in J20 mice (Figure 4), we next tested whether GNE-0723 could also reduce the ED 
phenotype in J20 mice. As observed in Scn1a-KI mice, EDs and 12- to 20-Hz power 
aberrantly increased during the two EEG sessions as mice decreased their exploratory 
activity (Figures 6 and S5). GNE-0723 reduced 12- to 20-Hz power in both WT and J20 
mice (Figures 6A and 6B) and reduced the rate of EDs in J20 mice (Figures 6C–6E). As 
expected, 12- to 20-Hz power correlated negatively with locomotor activity (Figure 6F) and 
positively with ED rate (Figure 6G). As in the Scn1a-KI mice, GNE-0723 reduced both 12- 
to 20-Hz power and ED rate in J20 mice without altering the relationship between the two 
(Figure 6G) and without altering locomotor activity (Figure S5A) or gamma oscillatory 
power (Figure S5B), suggesting that the reduction of 12- to 20-Hz power is upstream of the 
reduction of EDs. Thus, enhancing GluN2-containing NMDARs with GNE-0723 reduces 
epileptiform brain activity in two distinct mouse models with EDs.
Chronic GNE-0723 Treatment Ameliorates Memory Impairments in Scn1a-KI and J20 Mice
To determine whether chronic GNE-0723 treatment ameliorates cognitive deficits in J20 and 
Scn1a-KI mice, we orally treated J20 and Scn1a-KI mice and their respective littermate WT 
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controls with 3 mg/kg GNE-0723 or vehicle every other day for 5 weeks (Figure S6A). We 
used this regimen because this dose was effective at modulating oscillatory rhythms and 
lowering epileptiform discharges in J20 and Scn1a-KI mice, and every other day dosing 
achieved sustained brain exposure with total GNE-0723 concentrations of ~0.2 μM observed 
48 h after the last dose (Figures S6B and S6C).
Cognitive performance was assessed by the Morris water maze (MWM) test in J20 mice. 
After 2 weeks of treatment, vehicle- and GNE-0723-treated J20 mice showed similar 
impairments in the hidden platform component of the MWM test as indicated by increased 
swim distance to reach the platform compared to WT groups (Figure 7A, left). However, an 
early probe trial 24 h after 3 days of MWM training revealed a significant quadrant 
preference (reference memory) in GNE-0723-treated J20 mice, but not in vehicle-treated J20 
mice (Figure 7B, left), indicating that GNE-0723 enhances memory retention in J20 mice. 
After 5 days of MWM training, all groups had significant quadrant preference, albeit 
stronger preference in WT groups (Figure 7B, right). Next, we challenged the mice to locate 
a smaller hidden platform for 3 extra days of hidden MWM training (Figure 7A, right). 
Interestingly, under these conditions, all groups showed comparable performance during 
training and the 24-h probe trial thereafter (Figure 7C, left). However, a late 196-h probe 
trial revealed that GNE-0723-treated J20 mice and WT groups still remembered the location 
of the platform and spent more time in the correct target quadrant, whereas vehicle-treated 
J20 mice exhibited no target preference (Figure 7C, right). Notably, two-way ANOVA 
showed significant treatment (p = 0.009) and genotype (p = 0.025) effects with no genotype 
3 treatment interaction, indicating that GNE-0723 improved memory retention in both WT 
and J20 mice. Thus, GNE-0723 treatment improved memory retention in J20 mice (Figure 
7B, left) and improved long-term memory consolidation in J20 and WT mice (Figure 7C, 
right). This cognitive benefit in the WT mice suggests that enhanced memory may not 
necessarily be secondary to reduced epileptiform activity in the J20 mice but may be due to 
the effects of NMDAR enhancement on oscillatory rhythms.
Cognitive performance in Scn1a-KI mice was assessed in the contextual fear conditioning 
test, because Scn1a-KI mice did not show robust cognitive deficits in the MWM test 
(Figures S6D and S6E). Compared to WT controls, vehicle- and GNE-0723-treated Scn1a-
KI mice exhibited impaired freezing response (fear learning) to foot shocks during 
contextual fear conditioning training (Figure 7D). However, GNE-0723-treated Scn1a-KI 
mice showed improved contextual fear learning compared to vehicle-treated Scn1a-KI mice 
(Figure 7D, training), suggesting that GNE-0723 enhances fear learning in Scn1a-KI mice. 
During the 24-h recall test, both vehicle- and GNE-0723-treated Scn1a-KI mice exhibited 
comparable freezing. However, the 48-h recall test in a similar environment showed that 
GNE-0723-treated Scn1a-KI mice had improved memory retention compared to vehicle-
treated Scn1a-KI mice. Thus, GNE-0723 improved both learning and memory recall in the 
fear conditioning test. The effects of GNE-0723 on fear memory could not be assessed in 
J20 mice, because J20 mice did not show robust cognitive deficits in the fear conditioning 
test (Figure S6F).
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DISCUSSION
GluN2A-subunit-containing NMDAR allosteric potentiation had contrary behavioral and 
brain oscillatory effects to NMDAR blockade in vivo, including reduced locomotor activity 
and broadly decreased EEG oscillatory power. Aberrant increases of low-frequency 
oscillatory power reflect network hypersynchronization (Boly et al., 2017; Vaudano et al., 
2017; Matsumoto et al., 2013) and may contribute to the pathophysiology of DS and AD 
(Palop and Mucke, 2016). Consistently, low doses of GNE-0723 reduced aberrantly 
increased low-frequency (12–20 Hz) oscillatory power, ameliorated epileptiform activity, 
and improved cognitive functions in mouse models of DS and AD. Thus, GluN2A PAMs 
could represent a potential therapeutic strategy for normalizing pathological network activity 
and cognitive functions in diseases with network hypersynchrony, such as epilepsy and AD. 
Interestingly, GNE-0723 treatment also modulated low-frequency oscillations and improved 
memory retention in wild-type mice, indicating that the pro-cognitive effects of GNE-0723 
do not necessarily depend on its antiepileptic properties.
Potential Mechanisms of NMDAR Modulator Effects on Brain Rhythms
The behavioral effects of NMDAR blockade in rodents, such as hyperactivity and 
stereotypies, are well established and have been used to model the positive symptoms of 
schizophrenia (Adell et al., 2012). NMDAR antagonists increase the power of both low- and 
high-frequency oscillations (Lazarewicz et al., 2010), indicative of hypersynchronous 
oscillatory rhythms. The cellular effects of (+)-MK-801 treatment, including reduced fast-
spiking interneuron activity (Homayoun and Moghaddam, 2007) and increased expression 
of activity-dependent immediate early genes in pyramidal neurons (Gao et al., 1998; Hughes 
et al., 1993), suggest that suppressed inhibitory interneuron firing and increased excitatory 
neural activity may underlie the network effects, which manifest as increased locomotor 
activity and increased EEG power.
In contrast, in vivo effects of GNE-0723 involve reduced low-frequency (12–20 Hz) 
oscillatory power, a frequency band associated with brain resting state and network 
hypersynchrony in DS and AD models (Figure 4). Thus, GNE-0723 treatment seems to 
modulate brain state, favoring active states and desynchronized neuronal activity. 
Recordings from acute brain slices show that GNE-0723 can enhance NMDAR currents in 
both pyramidal cells and PV interneurons (Figure 2), suggesting that both cell types 
contribute to in vivo effects of GNE-0723. However, the relative effects of GNE-0723 on 
excitatory and inhibitory neurons in vivo will ultimately depend on the level of GluN2A-
containing NMDAR activation in each neuron type and its downstream functional effects. 
As with NMDAR antagonists, it is tempting to speculate that the effects of GluN2A-
containing NMDAR activation on circuit function in vivo may have a predominant effect on 
inhibitory interneurons, because these cells are more depolarized and fire action potentials at 
high rates, providing ongoing depolarization, removal of Mg2+ block, and basal NMDAR 
activity (Cohen et al., 2015; Homayoun and Moghaddam, 2007). Supporting this notion, 
GNE-0723 suppressed locomotor and rearing activity in a GluN2A- and dose-dependent 
manner, consistent with enhanced inhibition and general sedation, and reduced low-
frequency oscillatory power observed in WT mice (Figure 3), an effect similar to GABAA 
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PAMs, such as the benzodiazepine lorazepam (Saletu et al., 2006). However, GNE-0723 
does not cause the paradoxical increase in EEG power above 15 Hz that is a hallmark of 
benzodiazepines (van Lier et al., 2004), suggesting that the therapeutic profile of an GluN2A 
PAMs is likely to be different from benzodiazepines.
Consistent with restoration of interneuron-dependent network functions, GNE-0723 
treatment rescued excessive low-frequency oscillatory power and epileptiform activity in the 
DS mouse model (Figure 5). Nav1.1 is predominately expressed by inhibitory interneurons, 
including PV and somatostatin interneurons, and impaired inhibitory function has been 
proposed as a major pathogenetic mechanism in DS (Catterall et al., 2010; Ogiwara et al., 
2007; Rubinstein et al., 2015; Tai et al., 2014; Yamakawa, 2009; Yu et al., 2006). The J20 
mouse model of AD also features reduced Nav1.1 expression levels and network 
hypersynchrony. Restoring interneuron function by Nav1.1-BAC expression, Nav1.1-
overexpressing interneuron transplants or treatment with the anticonvulsant drug 
levetiracetam can reduce the pathological EEG spikes in these mice (Martinez-Losa et al., 
2018; Sanchez et al., 2012; Verret et al., 2012). As with the DS model mice, GNE-0723 also 
reduced epileptiform activity in the J20 AD model mice (Figure 6), confirming a benefit of 
the GluN2A PAM in two separate models of network hypersynchrony and impaired 
interneuron function. In both models, we observed a strong relationship between oscillatory 
power and EDs, with EDs occurring more often during periods of reduced high-frequency 
and elevated low-frequency oscillatory power (Figure 4), which is consistent with 
intracranial EEG measurements in epilepsy patients (Matsumoto et al., 2013). The 
predominant effect of 3 mg/kg GNE-0723 in both disease models (and controls) was to 
significantly reduce low-frequency oscillatory power and to reduce the rate of EDs. 
Interestingly, GNE-0723 treatment did not affect the relationship between low-frequency 
oscillatory power and ED rate in either model, suggesting that the reduction in low-
frequency oscillatory power could be sufficient to drive the suppression of epileptiform 
activity.
Potential Mechanisms of NMDAR Modulator Effects on Memory Retention
Prolonged reduction of network hypersynchrony in J20 and Scn1a-KI mice can provide 
cognitive benefit (Gheyara et al., 2014; Han et al., 2012; Martinez-Losa et al., 2018; Sanchez 
et al., 2012; Verret et al., 2012). We hypothesized that chronic GNE-0723 treatment would 
also be beneficial for cognitive functions because it had antiepileptic properties. During 
ongoing GNE-0723 treatment, we observed improved reference memory in treated J20 mice 
in an early probe trial after 3 days of water maze training. Remarkably, we also observed 
increased memory retention in both J20 and NTG mice when tested 8 days after training. 
The improved memory retention in WT mice suggests potentiating GluN2A-subunit-
containing NMDARs can have beneficial effects on memory even outside of the context of 
impairments driven by pathological network hypersynchrony. Because GNE-0723 reduces 
low-frequency oscillatory activity, which is associated with resting brain states and increased 
synchrony, we speculate that the pro-cognitive effects of GNE-0723 might also be mediated 
by promoting brain rhythms that favor active brain states. Consistent with the J20 behavioral 
data, we also observed enhanced memory formation in treated Scn1a-KI mice during the 
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training session of the fear conditioning test and enhanced memory retention during the 48 h 
recall test.
Although we have provided speculation on plausible roles of enhancement of synaptic 
NMDARs in pyramidal neurons and/or interneurons that could contribute to in vivo GluN2A 
PAM effects, it is also important to keep in mind the numerous sites of action that NMDAR 
PAMs could have in vivo. For example, GluN2A NMDARs are expressed in diverse neuron 
types throughout the various circuits of the brain and modulation of tonic or synaptic 
NMDAR currents or even presynaptic or astrocyte NMDARs could conceivably occur 
during in vivo treatment. It is also important to note that the majority of NMDARs in native 
brain tissue are likely various triheteromeric assemblies, for example, composed of two 
GluN1 subunits and GluN2A/GluN2D subunits (interneurons) or GluN2A/GluN2B subunits 
(interneurons and pyramidal cells), which are likely potentiated by GNE-0723 with varying 
potency. Thus, additional studies will be needed to identify the GluN2A-subunit-containing 
NMDAR assemblies, the cell types, and the circuits responsible for the cognitive benefits 
driven by activation of GluN2A subunit-containing NMDARs in vivo.
Therapeutic Potential of NMDAR PAMs
Although the results with DS and AD mouse models suggest therapeutic promise of 
GluN2A PAMs, challenges remain for realizing this type of approach. A concern with 
glutamate receptor PAMs, including NMDAR PAMs, is that, in addition to beneficial effects 
at lower doses, there is the potential for neuronal over-excitation and triggering of seizures at 
higher doses, as is seen with AMPAR and mGluR PAMs (Shaffer et al., 2013; Yang et al., 
2016). With this concern in mind, we have limited dosing of GNE-0723 to the lower dose (3 
mg/kg) in order to focus on effects on physiological function, while avoiding potential 
adverse effects at higher doses.
Although NMDAR potentiation can be achieved in different ways (e.g., enhancing peak 
current or slowing deactivation; Hackos and Hanson, 2017), we do not currently have 
compounds with different modes of potentiation that can be compared in vivo, and it 
remains unclear which in vitro properties of GNE-0723 are important for the in vivo effects. 
Thus, future development of in vivo GluN2A PAM tools with contrasting modes of action 
could provide further insight into the potential impacts of NMDAR enhancement on circuit 
function. Various mutations in GRIN2A, the gene encoding GluN2A, have been identified in 
syndromic causes of childhood epilepsy, including both loss of function and gain of function 
(Addis et al., 2017; Carvill et al., 2013; Gao et al., 2017; Lemke et al., 2013; Lesca et al., 
2013; Serraz et al., 2016; Yuan et al., 2014), suggesting complex relationships between 
GluN2A-containing NMDAR function and network excitability during development. 
Interestingly, a recent study showed that a compound closely related to GNE-0723 could 
rescue loss-of-function phenotypes seen in NMDAR currents measured from cells 
expressing NMDARs with epilepsy patient GRIN2A mutations (Addis et al., 2017).
Finally, although we originally pursued GluN2A-selective PAMs based on theoretical 
concerns over potential excitotoxicity with overactivation of GluN2B NMDARs 
(Hardingham et al., 2002; Hu et al., 2009; Li et al., 2011), it has not been definitively 
established that GluN2B overactivation actually plays a detrimental role in the context of 
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AD (Hanson et al., 2014; Texidó et al., 2011). Thus, it remains possible that other PAMs 
without GluN2A selectivity could also show efficacy in AD mouse models.
Overall, GNE-0723 represents a useful tool compound that reveals the in vivo consequences 
of pharmacological enhancement of GluN2A-containing NMDARs. The profile of effects 
suggests GluN2A PAMs can act to normalize hyperactive brain networks and can enhance 
memory retention in DS and AD mouse models. Future studies using this tool compound 
and building on these results should reveal new insight into the physiological roles of 
NMDARs in different cell types and circuits. Following the initiation of in vivo work with 
GNE-0723 reported here, we have also discovered another GluN2A PAM, GNE-5729, 
which potentiates NMDAR currents in a similar manner as GNE-0723 and exhibits even 
better pharmacokinetic properties, which should be useful for future in vivo studies 
(Villemure et al., 2016). The findings of the present study indicate that NMDAR PAMs 
could have therapeutic potential not only in disorders like schizophrenia, where the 
pathophysiology is thought to involve NMDAR hypofunction, but more broadly in diseases 
where network hyperexcitability may contribute to pathology or symptoms, including DS, 
other forms of epilepsy, and AD.
STAR★METHODS
LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Jesse Hanson (hanson.jesse@gene.com). This study did not 
generate new unique reagents.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice were housed at AAALAC-approved facilities. Animal studies were approved by the 
Institutional Animal Care and Use Committees and were conducted in accordance with the 
NIH Guide for the Care and Use of Laboratory Animals. Food and water were available ad 
libitum. Pharmacokinetic studies (Figure 1) were performed using male C57BL/6 mice from 
Charles River Laboratories (Hollister, CA, USA). Brain slice electrophysiology experiments 
(Figure 2) used PV-cre mice crossed to tdTomato reporter mice on the C57BL/6J 
background (Tanahira et al., 2009). Locomotor studies with GNE-0723 (Figure 3) used 
GluN2AKO and WT littermate mice on the C57BL/6J background (Kadotani et al., 1996). 
Locomotor studies with MK-801 (Figure S2) and EEG brain state studies (Figure 3) used 
C57BL/6J mice from The Jackson Laboratory (Sacramento, CA, USA). EEG and behavioral 
studies (Figures 4, 5, 6, and 7) used Scn1a-KI and littermate control mice on a C57BL/6J 
background (Ogiwara et al., 2007) and J20 and littermate control mice on a 50% C57BL/6J 
and 50% FVB/N background (Verret et al., 2012). Unless indicated otherwise, EEG and 
behavioral measurements were done in sex-mixed groups in adult mice using automated 
recording systems by investigators who were unaware of the genotype or treatment of the 
mice. The age of mice is indicated in the figure legends.
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METHOD DETAILS
Dosing—Doses of GNE-0723 were administered via oral gavage as 0.5% methylcellulose 
and 0.2% Tween 80 (MCT) suspension. Vehicle was used as control. Drug doses for 
GNE-0723 are expressed as mg/kg of free base. (+)-MK-801 and (−)-MK-801 were 
dissolved in saline and administered IP; doses are expressed as mg/kg of the maleate salt. 
Application volume was 5–10 mL/kg.
Pharmacokinetics—After PO dose administration, blood and brain samples were 
collected from mice at the indicated times post-dose. Blood samples were collected into 
K2EDTA Microtainer tubes (Becton Dickinson; Franklin Lakes, NJ, USA) and were 
centrifuged at a relative centrifugal force (RCF) of 2,800 × g for 5 minutes. Plasma was 
decanted and stored at −80°C until thawed for analysis. The concentrations of GNE-0723 in 
plasma and brain samples were determined by liquid chromatography–tandem mass 
spectrometry (LC-MS/MS) assay using indomethacin as an internal standard (IS). The 
unbound fractions in plasma and brain homogenate of GNE-0723 were determined in a 48-
well rapid equilibrium dialysis (RED) device using a dialysis membrane with a molecular 
weight cut-off value of 8,000 Da (Pierce Biotechnology, Rockford, IL, USA). The unbound 
fraction in plasma and unbound fraction in the brain homogenate were calculated as a ratio 
of buffer concentration to plasma or brain concentration, and these values were used to 
determine the unbound plasma and brain concentrations in the samples.
Cell-line rapid solution exchange electrophysiology—Whole-cell patch-clamp 
recordings from CHO cell lines with doxycycline-inducible (Dox) GluN1/GluN2A were 
performed using the Dynaflow Resolve rapid solution exchange system (Cellectricon, 
Mölndal, Sweden) as previously described (Hackos et al., 2016). Except where otherwise 
indicated experiments were performed at RT. For the set of experiments performed at 37°C, 
a DFT100201 Temperature Controller Unit and DFT100202 Heat Stage were added to the 
Dynaflow system (Cellectricon). Intracellular solution contained (in mM): 140 CsF, 10 
NaCl, 1.5 MgCl2, 5 EGTA, 10 HEPES, adjusted to pH 7.2 with CsOH. The extracellular 
recording solution contained (in mM): 150 NaCl, 3 KCl, 1 CaCl2, 5 glucose, 10 HEPES, 
adjusted to pH 7.4 with NaOH.
Cell-line synaptic-like glutamate application—Whole-cell patch-clamp recordings 
were made from CHO cell lines as above and 100 μM Glu was applied for a 5ms pulse 
duration using a 2-barrel theta tube perfusion system with a P-601.30L PiezoMove linear 
actuator (PI, USA).
Brain slice electrophysiology—Mice were anesthetized using isoflurane prior to 
decapitation and 300-mm-thick coronal slices were prepared with a vibrating sectioning 
system (Leica, Germany). Whole-cell recordings were made from layer 5 pyramidal neurons 
or PV-positive interneurons in coronal cortical slices using 2–3-month-old PV-cre × 
tdTomato mice. Recordings were made at RT in oxygenated artificial cerebrospinal fluid 
(ACSF) containing (in mM) 127 NaCl, 2.5 KCl, 1.3 MgSO4, 2.5 CaCl2, 1.25 Na2HPO4, 25 
NaHCO3, 25 glucose. Slices were prepared in ice-cold oxygenated ACSF with the MgSO4 
concentration elevated to 7 mM, NaCl replaced with 110 mM choline, and with 11.6 mM 
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Na-ascorbate and 3.1 mM Na-pyruvate. Slices recovered in this same solution at 34 C for 30 
min before being transferred to regular ACSF at RT for storage for at least 1 hour prior to 
recording. tdTomato fluorescence was visualized using a Zeiss Axio Examiner.Z1 
microscope. For current-clamp recordings, intracellular solution consisted of (in mM) 120 
K-gluconate, 20 KCl, 0.5 EGTA, 10 HEPES, 2.5 MgCl2, 4 Na2ATP, 0.3 NA3GTP and 10 
phosphocreatine. For voltage clamp experiments, the K-gluconate was replaced with Cs-
methanesulfonate; KCl was replaced with CsCl; and 5 mM QX-314 Cl was added. NMDAR 
EPSCs were measured in response to electrical stimulation (0.2 ms pulse duration in 
constant current mode with intensity adjusted to elicit a baseline EPSC in the 25–100 pA 
range) 100–200 mm away from the recorded cell at 30 s inter-stimulus intervals, and were 
recorded at a holding potential of −70 mV in the presence of reduced Mg2+ (0.5 mM). 
Signals were low pass filtered at 10 kHz. NMDAR EPSCs were isolated using 10 μM 
NBQX disodium salt and 100 μM PTX. 100 μM AP5 applied at the end of the recording 
confirmed isolation of pure NMDAR EPSCs. Series resistance was monitored and 
recordings were discarded if series resistance changed by more than 15% or if apparent loss 
of voltage clamp control occurred as reflected by a sudden change in the EPSC waveform. 
NMDAR EPSC peak current amplitude, current area, and decay time constants were 
measured using Clampfit and average values during the last 5 minutes of the experiment are 
reported as a percentage of the baseline value.
Intracranial EEG comparison of GNE-0723 and MK-801 in WT mice
Intracranial EEG surgery: Male mice (2–3 months old) were anesthetized with isoflurane 
(~3.5% at 700 mL/min) and given a subcutaneous injection of 4 mg/kg of Carprofen (Henry 
Schein, Dublin, OH, USA). A prefabricated EEG/EMG headmount (model #8201 Pinnacle 
Technologies, Lawrence KS, USA) was secured to the skull with two 0.10” screws anterior 
(#8209, Pinnacle Technologies) and two 0.12” screws posterior (#8212, Pinnacle 
Technologies) implanted at the following stereotactic coordinates relative to bregma (lateral, 
anterior in mm): reference electrode −1.2, −2.5 (left visual cortex); ground electrode −1.2, 3 
(left frontal cortex); recording electrode: 1.2, 3 (right frontal cortex). Silver epoxy (#8226, 
ResinLab, Germantown WI, USA) was then applied to the screws to ensure electrical 
conduction, and the entire assembly was secured to the skull with VetBond (#1469SB 3M, 
Saint Paul MI, USA) and dental acrylic (#1230, Lang Dental Manufacturing, Wheeling IL, 
USA). The EMG electrodes were inserted into small pockets in the nuchal muscle.
Synchronized Video
EEG, and EMG recordings: Mice were recorded on two consecutive days during the 
middle of the light cycle. Each recording session lasted 150 minutes. Mice were dosed with 
vehicle immediately before recording on day 1 and with vehicle or compound on day 2. The 
first 20 minutes of each recording were excluded from further analysis to allow time for the 
drug to reach maximal brain exposure. Recordings occurred in four 25.4 cm diameter 
cylindrical acrylic arenas with bedding using 4-channel video/tethered-EEG systems 
(Pinnacle Technologies). EEG/EMG data were sampled with 16 bit resolution at 500 Hz, 
and band-pass filtered between 0.5 and 125 Hz for EEG and 10 to 125 Hz for EMG. 
320×240 pixel grayscale videos were captured at 10 fps.
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Video EEG/EMG analysis: EEG/EMG data were exported to European Data Format (.edf) 
files for analysis in MATLAB 2014a (Mathworks, Natick, MA, USA). Spectrograms were 
calculated by the multitaper method with three tapers, 1 s windows, 0.1 s steps, and 2 Hz 
bandwidths using the Chronux toolbox (http://chronux.org) (Mitra and Bokil, 2008). The 
spectrograms were averaged into 5 s epochs for sleep state classification using a 3-step semi-
automated hierarchical algorithm based on the EMG and EEG channel 2 signals (Louis et 
al., 2004). Briefly, the step 1 threshold was manually chosen to best separate the EMGRMS 
signal (above threshold = Active Wake, below threshold = next step), the step 2 threshold 
separated (δ*α)/(β *γ) (above = NREM, below = next step), and the step 3 threshold 
separated (θ2)/(δ *α) (above = REM, below = Quiet Wake). The frequency bands for sleep 
scoring were defined as: delta (δ) = 0.5 to 6 Hz, theta (θ) = 6 to 10 Hz, alpha (α) = 10.5 to 
15 Hz, beta (β) = 22 to 30 Hz, and gamma (γ) = 35 to 56 and 64 to 100 Hz to avoid potential 
60 Hz noise. We defined γ = 30 to 80 Hz for calculating the scatterplots in Figures 3E and 
3F to maintain consistency with the EEG experiments in the Scn1a-KI and J20 mice. For 
Figures 3E, 3F, and S3 the average day 2 (drug) EEG power for each mouse was normalized 
by the day 1 (vehicle) power for that mouse, and by the average change in EEG power from 
day 1 to day 2 for the vehicle-dosed mice. These normalizations allowed the drug effects to 
be isolated from changes in EEG power due to habituation to the arena across days.
Scn1a-KI and J20 EEG recordings on freely moving mice—Sex-mixed 9–13-
month-old Scn1a-KI and 7 – 11-month-old mice were implanted and recorded for video 
EEG monitoring as (Martinez-Losa et al., 2018; Verret et al., 2012). Cortical EEG 
recordings were performed on freely moving mice in an open-field chamber (40 × 40 × 30 
cm; automated Flex-Field/Open Field Photobeam Activity System; San Diego Instruments, 
San Diego, CA, USA) using the EEG Harmonie software (version 5.0b, Stellate, Natus 
Neurology, Middleton, VA, USA). A crossover design was used for the drug treatment 
studies. We first recorded a 50-min EEG pretreatment session on day 1 followed by a second 
50-min EEG treatment session on day 3, in which mice orally received vehicle or 3 mg/kg 
GNE-0723 treatments 30 minutes before the recording session started. Mice were kept in 
regular mouse cages between recording sessions, including the 30-min period after dosing. 
After a washout period of > 3 weeks, we repeated the same experimental design but mice 
received the alternative treatment (crossover design). The number of epileptiform discharges 
(EDs) was automatically detected with a Gotman spike detector (threshold 6; Harmonie, 
Stellate). For spectral analyses, 50-min segments of unfiltered EEG recordings (sampling 
rate 200 Hz) from freely moving mice were analyzed using LabChart 7 Pro software (AD 
Instruments, Colorado Springs, CO, USA). The 12–20-Hz (α–β) and 30–80-Hz (γ) bands 
were used to calculate the low- and high-frequency oscillatory power, respectively. Fast 
Fourier transform (FFT) was applied with a Hann cosine-bell window with 50% overlap 
between windows of 500-ms epochs and a 512 point FFT size to obtain a resolution of 0.39 
Hz. The low- and high-frequency oscillatory power values for each 500-ms epoch were 
further averaged over 60 s of EEG recording, using the median values, to remove potential 
noise. Because high- (30–80 Hz) and low- (12–20 Hz) frequency oscillatory power were 
associated with high and low behavioral activity respectively (Figure 4), we normalized low-
frequency (12–20 Hz) oscillatory power to resting periods and high-frequency (30–80 Hz) 
power to active periods for each mouse, which represent the behavioral states with the 
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lowest oscillatory power for each frequency band. To calculate relative 30–80 Hz power, the 
y-intercept at 0 movements/min was calculated for each mouse by linear regression analysis 
using the 50-min data points of movement frequency (x; beam breaks/min) and the absolute 
30–80 Hz power (y; V2) for the pretreatment session. The y-intercept of the absolute 30–80 
Hz power value for the pretreatment EEG session was used to normalize the 100 min of 
EEG data points of pretreatment and treatment sessions within each mouse. Thus, 1.0 
indicates the high-frequency (30–80) Hz power at resting during the pretreatment session. To 
calculate relative 12–20 Hz power, the average of the absolute 12–20 Hz power (V2) during 
periods of intermediate locomotor activity (20–100 beam breaks/min) was used to normalize 
the 100 min of EEG data points of 12–20 Hz power within each mouse. Thus, 1.0 indicates 
the 12–20 Hz power during active periods in the pretreatment session. Finally, normalized 
signals from both hemibrains were averaged to obtain the power values for each mouse.
Behavioral testing
Open field test: Sex-mixed 3–6-month-old (GNE-0723 experiments in GluN2AKO and WT 
littermates, Figure 3) and 2–3-month-old male mice (MK-801 experiments, Figure S2) were 
maintained on a 14/10 hour light/dark cycle and tested during the light phase. PAS™ open-
field recording systems (San Diego Instruments, San Diego, CA, USA) consisted of 
transparent thermoplastic cages (40.5 (W) × 40.5 (L) × 38 (H) cm) surrounded by a 
locomotor frame and a rearing frame fitted with infra-red beams to automatically record 
horizontal locomotor activity (3 cm above floor) and rearing activity (7.5 cm above floor), 
respectively. The total number of beam breaks for both ambulatory locomotor activity and 
rearing were obtained for bin sizes of 10 min and reported as ambulatory beam breaks and 
rearings per minute, respectively. Locomotor analyses are based on aggregated data from a 
30-min time window beginning 30 min after dosing. This time window corresponds to the 
40–60 min bins for GNE-0723 and 70–90 min bins for MK-801. Data were analyzed using 
one-way, between-subjects ANOVA. Post hoc comparisons were made using Tukey’s HSD 
in order to account for more than two comparisons between factors or factor levels. Analyses 
and graphs were generated using JMP 10.02 (SAS Institute, Cary, NC, USA). Four GluN2A 
KO mice that had seizures during weighing prior to dosing were excluded from locomotor 
analyses.
Morris water maze test: Cognitive function of sex-mixed 4–6-month-old J20 (Figure 7), 
10–12-month-old Scn1a-KI (Figure S6) and littermate control mice was assessed using the 
Morris water maze test. The pool is 122 cm in diameter containing opaque white water. The 
standard platform is 14×14 cm and the small platform is 10×10 cm. Mice were trained to 
locate a hidden platform based on spatial cues on surrounding walls. Each training day 
consists of 2 sessions 4 hours apart, each session is 2 trials 20–30min apart. As indicated, 
mice were trained for 5 (J20 mice) or 6 (Scn1a-KI mice) days with the standard platform. 
J20 mice received additional 3 days of hidden training with a small platform. The location of 
the hidden platform remained constant and the drop points of the mice were semi-randomly 
assigned. As indicated, one minute 24-hour probe trials were performed after 3 days and 
after the conclusion of the hidden platform training with the standard and small platforms. 
J20 mice received an additional one 192-hour probe trial after the hidden training. Activity 
of the mice were monitored using an EthoVision video tracking system (Noldus Information 
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Technology). Swim distance and latencies to reach the hidden platform were used to 
measure performance in training trials. Swim speed was not altered by chronic GNE-0723 
treatment (WT-Vehicle = 18.5 ± 0.4, J20-Vehicle = 19.6 ± 0.4, WT-GEN-0723 = 18.1 ± 0.5, 
J20-GEN-0723 = 18.9 ± 0.5; mean (cm/s) ± SEM). Percentage (%) time spent in the hidden 
platform target quadrant versus average % time spent in the other 3 quadrants were used to 
assess reference memory. Mice were single-housed for the duration of this test.
Contextual fear conditioning test: Cognitive function of sex-mixed 10–12-month-old 
Scn1a-KI (Figure 7), 4–6-month-old J20 (Figure S6) and littermate control mice was 
assessed using the contextual fear conditioning test. The test used 4 identical computer-
controlled chambers (28 × 21 × 22 cm) with 18 stainless steel floor rods connected to a 
shock scrambler and generator (4 mm diameter, 1.5cm apart) (Med Associates). On day one, 
mice were habituated in the chambers for 5min to record baseline freezing behavior, then 
mice were given four 1 s shocks (0.45mA) 2 min apart. For the 24-hour and 48-hour 
contextual recall tests, mice were placed in the same chambers for 5 min with identical (24-
hour recall) or similar (48-hour recall) configurations. Freezing behavior was automatically 
recorded by a video-tracking system and defined as the absence of any visible movement 
except respiration (motion threshold = 18, detection method = linear; Med Associates). Total 
activity during baseline was not altered by chronic GNE-0723 treatment (WT-Vehicle = 155 
± 8, J20-Vehicle = 194 ± 11, WT-GEN-0723 = 162 ± 14, J20-GEN-0723 = 177 ± 10; mean 
(average motion index) ± SEM). The chambers were cleaned with 70% ethanol after each 
mouse.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyses were done with STATA, Prism, or JMP. Graphs were generated with 
Prism or JMP. As indicated in the figure legends, differences among multiple means were 
assessed by one-way or two-way ANOVA and Bonferroni, Tukey, or Sidak’s post hoc tests. 
The p values are indicated in the figure panels with the following significance levels, *p < 
0.05, **p < 0.01, and ***p < 0.001 with two-tailed distribution tests. Null hypotheses were 
rejected at the 0.05 level.
Number (n) of mice or cells for all statistical analyses is indicated in each graph or in the 
legend. Unless indicated otherwise, values in figures and text are expressed as mean ± SEM. 
Statistical tests are indicated in the figure legends.
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Highlights
• AD and DS mice display aberrant 12- to 20-Hz oscillations associated with 
epileptic spikes
• GluN2A-NMDAR enhancement reduces aberrant oscillations and spikes in 
AD and DS mice
• Chronic GluN2A-NMDAR activation improves cognitive functions in AD and 
DS mice
• GluN2A PAMs could benefit brain disorders with hypersynchrony and 
cognitive deficits
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Figure 1. GNE-0723 Is an Activity-Dependent GluN2A NMDAR PAM with Suitable PK 
Properties for In vivo Use
(A) NMDAR current traces in Chinese hamster ovary (CHO) cells expressing GluN1/
GluN2A in response to pulses of increasing concentrations of glutamate (Glu) in the absence 
(control) or presence of 1 μM GNE-0723 (50 μM Gly was present in all solutions). Solution 
exchange was performed with the multichannel Dynaflow Resolve system at RT (Figure 1) 
or 37°C (Figure S1). To allow for potentially slow or Glu-dependent binding of GNE-0723, 
four consecutive 2-s pulses of 100 μM Glu were delivered in the presence of GNE-0723 (not 
shown) before measuring the response to different Glu concentrations.
(B) Quantification of NMDAR currents measured in response to 2-s pulses of 100 μM Glu in 
the absence or presence of 1 μM GNE-0723. Currents are shown normalized to the average 
current measured in the absence of GNE-0723. Note the significant increase in NMDA 
current area in the presence of GNE-0723 (n = 4/group; *p = 0.03 by Wilcoxon rank sum 
test).
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(C) Peak NMDA current responses to increasing Glu concentrations showed a significant 
left shift in the EC50 of Glu, reflecting greater Glu sensitivity of the NMDAR in the 
presence of GNE-0723 (n = 4/group; p = 0.03 by Wilcoxon rank sum test). Values are shown 
normalized to the maximal peak current at 100 μM Glu. (D) Total and calculated unbound 
plasma concentrations are shown following oral dosing with 1, 3, or 10 mg/kg GNE-0723 (n 
= 3 mice/time point; 2 to 3 months). The dashed black line represents the GNE-0723 EC50 
from cell-based assays (Hackos et al., 2016).
(E) Calculated unbound plasma and brain concentrations of GNE-0723 at 0.5–24 h after 
dosing with 3 mg/kg GNE-0723 (n = 3 mice/time point; 2 to 3 months).
(F–H) In order to more closely approximate in vivo synaptic activation of NMDARs, 
currents were recorded from the CHO cell line using piezo-electrode-controlled theta tube 
application of solutions. NMDAR currents were measured in response to 5-ms pulses of 100 
μM Glu (arrowhead) before (top) and after (bottom) application of 30 nM GNE-0723 (50 
μM Gly present in all solutions). Example traces illustrate the prominent effect of slowing of 
deactivation by GNE-0723, although enhancement of peak current was not evident (F). 
Repeated responses showed that 30 nM GNE-0723 activity-dependently potentiated 
NMDAR EPSC current area (G) and decay time constant (H) during repeated stimulation at 
30 s or 90 s inter-stimulus intervals (ISI), indicating use dependence of GNE-0723 effects. 
GNE-0723 or DMSO (vehicle control) was applied after stimulus number 0. GNE-0723 
significantly increased area and decay time constant of the NMDAR response measured at 
stimulus number 5 relative to baseline for the 30-s ISI (p < 0.05 and p < 0.001, respectively; 
n = 7) and 90-s ISI (p < 0.001 and p < 0.001; n = 6) conditions, but not in the DMSO 
condition (p = 0.78 and p = 0.36; n = 7). The amount of potentiation of the area and decay 
time were not significantly different between the 30-s ISI and 90-s ISI conditions (p = 0.31 
and 0.24). *p < 0.05; ***p < 0.001 by Student’s t test. Values are expressed as mean ± SEM 
(B, C, G, and H) or as mean ± SD (D and E).
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Figure 2. GNE-0723 Enhances Synaptic NMDAR Currents on Pyramidal Neurons and PV 
Interneurons
(A and B) Whole-cell recordings from pyramidal neurons (A) and PV interneurons (B) were 
made from cortical brain slices prepared from 2- to 3-month-old mice with tdTomato 
reporter gene expression driven by a PV-cre promoter. Neurons were filled with Alexa 488 
hydrazide during recording, and neuron types were verified by morphology and 
electrophysiological properties. Example current clamp recordings showing typical action 
potential firing patterns in response to current injection are shown for each type of neuron.
(C and D) Evoked pharmacologically isolated NMDAR EPSCs were measured in pyramidal 
neurons (C) and PV interneurons (D) before and after application of 0.3 μM GNE-0723. 
Average example traces from the 5 min of baseline (black) or the last 5 min of GNE-0723 
application (red) are shown inset. GNE-0723 significantly increased the average area of the 
NMDAR EPSC measured during the last 5 min of the experiment in the presence of the drug 
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compared to the 5 min before drug application in both pyramidal neurons (n = 11; p < 0.05) 
and PV interneurons (n = 10; p < 0.05). *p < 0.05 by Student’s t test.
(E and F) NMDAR EPSCs were measured in pyramidal neurons (E) and PV interneurons 
(F) before (black) and after (red) application of 1.0 μM GNE-0723. GNE-0723 significantly 
increased the average area of the NMDAR EPSC measured during the last 5 min of the 
experiment in the presence of the drug compared to the 5 min before drug application in 
pyramidal neurons (n = 5; p < 0.05) and PV interneurons (n = 8; p < 0.05). The increasing 
potentiation throughout the GluN2A PAM application indicates that equilibrium receptor 
occupancy and maximal potentiation may not have been achieved during the time frame of 
these experiments, which is consistent with the use-dependent potentiation observed with 
recombinant NMDARs.
All values are expressed as mean ± SEM; *p < 0.05 by Student’s t test. See also Figure S1.
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Figure 3. GNE-0723 Reduces Locomotor Activity in a GluN2A-Dependent Manner and Reduces 
EEG Oscillation Power
(A–D) Locomotor activity of sex-mixed 3- to 6-month-old GluN2A KO mice and wild-type 
(WT) littermate controls after treatment (time 0) with vehicle or 3, 6, or 10 mg/kg 
GNE-0723 (n = 13–17 per group). The number of ambulatory beam breaks and rearings are 
shown in 10-min bins. Bar charts show average events/min from a 30-min time window 
beginning 30 min after dosing (40–60 min). Higher doses of GNE-0723 treatment 
significantly reduced ambulatory activity (10 mg/kg; A) and rearings (6 or 10 mg/kg; B) in 
WT mice. *p < 0.05; ***p < 0.001 versus vehicle control by Tukey’s post hoc tests. 
GNE-0723 treatment did not alter ambulatory activity in GluN2A KO mice (C; one-way 
ANOVA; p = 0.90) or rearings (D; one-way ANOVA; p = 0.71).
(E and F) EEG power across frequencies during active wake and NREM was normalized to 
vehicle-treated animals to assess the oscillatory effects of GNE-0723 at 3, 6, and 10 mg/kg 
in 2- to 3-month-old male mice. GNE-0723 at 3 mg/kg reduced 12- to 20-Hz, but not 30- to 
80-Hz, oscillatory power during active wake (E) and NREM (F). Higher doses (6 and 10 
mg/kg) of GNE-0723 reduced 12- to 20-Hz and 30- to 80-Hz oscillatory power during active 
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wake (E) and NREM (F). Vehicle = 9 (active wake) and 6 (NREM) mice; 3 mg/kg = 8 and 7; 
6 mg/kg = 9 and 8; 10 mg/kg = 7 and 6, respectively). *p < 0.05; **p < 0.01; ***p < 0.001 
versus vehicle by two-way ANOVA (factors: frequency band and dose level) and Sidak’s 
post hoc tests. See also Figures S2 and S3.
Values are expressed as mean ± SEM (A–D) or mean ± 95% confidence interval (CI) (E and 
F).
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Figure 4. Brain Oscillatory Rhythms and Behavioral Activity Are Strongly Associated with 
Epileptiform Activity in Scn1a-KI and J20 Mice
Oscillatory activity and epileptiform discharges (EDs) were measured for 50 min from 
cortical EEG recordings in sex-mixed 9- to 13-month-old Scn1a-KI (n = 10) and 7- to 11-
month-old J20 (n = 18) mice (2 crossover design sessions).
(A) Traces of EEG recordings from the left and right parietal cortex (top) and movement 
(black, bottom) and ED rates (blue, bottom) for representative Scn1a-KI (left) and J20 
(right) mice. Arrows denote EDs.
(B) EEG spectrograms (top) and oscillatory power of 12–20 Hz (red, bottom) and 30–80 Hz 
(green, bottom) for the same Scn1a-KI (left) and J20 (right) mice shown in (A).
(C) Traces of ED rate (blue) and 30- to 80-Hz power (green) for representative Scn1a-KI and 
J20 mice (left). Linear relationship between 30- to 80-Hz power and ED rate in all Scn1a-KI 
and J20 mice (right) is shown. 30- to 80-Hz power is negatively correlated with ED rate in 
Scn1a-KI and J20 mice (p < 0.001 by linear regression slope test).
(D) Traces of EDs (blue) and 12- to 20-Hz power (red) for the same Scn1a-KI and J20 mice 
shown in (C) (left). Linear relationship between 12- to 20-Hz power and ED rate in all 
Scn1a-KI and J20 mice is shown. 12- to 20-Hz power is positively correlated with ED rate in 
Scn1a-KI and J20 mice (p < 0.001 by linear regression slope test).
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Figure 5. GNE-0723 Reduces Low-Frequency (12–20 Hz) Oscillatory Power and Epileptiform 
Activity in Scn1a-KI Mice
Oscillatory activity and EDs were measured from cortical EEG recordings in sex-mixed 9- 
to 13-month-old WT (n = 9–10) and Scn1a-KI (n = 17–19) mice during a 50- min 
pretreatment session and during a 50-min session beginning 30 min after administration of 
vehicle or 3 mg/kg GNE-0723 in a crossover design (pretreatment and treatment sessions 
separated by dashed line). See STAR Methods for details.
(A) Minute-by-minute 12- to 20-Hz oscillatory power during the 50 min before 
(pretreatment) and after vehicle or 3 mg/kg GNE-0723 treatment. During the pretreatment 
session, Scn1a-KI mice exhibited elevated 12- to 20-Hz power as they habituated to the open 
field and their exploratory activity decreased (***p < 0.001 by repeated-measures ANOVA 
and Bonferroni post hoc test for the 50-min pretreatment session). GNE-0723 significantly 
reduced 12- to 20-Hz power in WT and Scn1a-KI mice (***p < 0.001 by repeated-measures 
ANOVA and Bonferroni post hoc test for the 50-min treatment session).
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(B) 12- to 20-Hz oscillatory power averaged over the entire pretreatment and treatment 
sessions. During the pretreatment session (left), both Scn1a-KI mouse groups had similar 
increases in 12- to 20-Hz power compared to WT control groups. 3 mg/kg GNE-0723 
treatment (right) reduced 12- to 20-Hz power in WT and Scn1a-KI mice compared to 
vehicle-treated groups. *p < 0.05; **p < 0.01 by ANOVA and Bonferroni post hoc test.
(C) Traces of EEG recordings illustrating EDs in Scn1a-KI mice at two different temporal 
resolutions.
(D) Minute-by-minute ED rates before and after vehicle or 3 mg/kg GNE-0723. GNE-0723 
treatment reduced EDs in Scn1a-KI mice (***p < 0.001 by repeated-measures ANOVA and 
Bonferroni post hoc test for the 50-min treatment session).
(E) ED rate averaged over the entire pretreatment and treatment sessions. During 
pretreatment session (left), both Scn1a-KI mouse groups had similar ED rates. 3 mg/kg 
GNE-0723 treatment reduced ED rates in Scn1a-KI mice. **p < 0.01 by Student’s t test.
(F and G) 12- to 20-Hz oscillatory power as a function of locomotor activity (F) and ED rate 
(G) in vehicle- and GNE-0723-treated Scn1a-KI mice during the 50-min treatment session. 
Higher 12- to 20-Hz power strongly correlated with lower locomotor activity (F) and higher 
ED rate (G). GNE-0723 treatment reduced 12- to 20-Hz power particularly during periods of 
low locomotor activity (F; ***p < 0.001 by linear regression analysis and slope test) but did 
not significantly change the tight relationship between EDs and low-frequency, 12- to 20-Hz 
oscillations (G).
Values are expressed as mean ± SEM (A–E) or 95% CI (F and G). See also Figure S4.
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Figure 6. GNE-0723 Reduces Low-Frequency (12–20 Hz) Oscillatory Power and Epileptiform 
Activity in J20 Mice
Oscillatory activity and epileptiform discharges were measured from cortical EEG 
recordings in sex-mixed 7- to 11-month-old WT and J20 mice (n = 9 WT mice per group; n 
= 16–18 J20 mice per group) during a 50-min pretreatment session and during a 50-min 
session beginning 30 min after administration of vehicle or 3 mg/kg GNE-0723 in a 
crossover design (pretreatment and treatment sessions separated by dashed line). See STAR 
Methods for details.
(A) Minute-by-minute 12- to 20-Hz oscillatory power before and after vehicle or 3 mg/kg 
GNE-0723 treatment. 12- to 20-Hz power increased in all mouse groups as they habituated 
to the open-field arena. 3 mg/kg GNE-0723 significantly reduced 12- to 20-Hz power in WT 
and J20 mice (***p < 0.001 by repeated-measures ANOVA and Bonferroni post hoc test for 
the 50-min treatment session).
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(B) 12- to 20-Hz power averaged over the entire pretreatment and treatment sessions. During 
the pretreatment session (left), WT and J20 mouse groups had similar 12- to 20-Hz power. 
During the treatment session (right), 12- to 20-Hz power increased in vehicle-treated mice 
but decreased in GNE-0723-treated WT and J20 mice. **p < 0.01 by ANOVA and 
Bonferroni post hoc test.
(C) Traces of EEG recordings illustrating EDs in J20 mice at two different temporal 
resolutions.
(D) Minute-by-minute ED rates during the 50-min pretreatment and treatment sessions. 
GNE-0723 treatment reduced EDs in J20 mice (***p < 0.001 by repeated-measures ANOVA 
and Bonferroni post hoc test for the 50-min treatment session).
(E) ED rate averaged over the entire pretreatment and treatment sessions. During the 
pretreatment session (left), both J20 mouse groups had similar ED rates. 3 mg/kg GNE-0723 
treatment reduced ED rates in J2O mice. *p < 0.05 by Student’s t test.
(F and G) 12- to 20-Hz power as a function of locomotor activity (F) and ED rate (G) in 
vehicle- and GNE-0723-treated J20 mice during the 50-min treatment session. Higher 12- to 
20-Hz power strongly correlated with lower locomotor activity (F) and higher ED rate (G). 
GNE-0723 treatment reduced 12- to 20-Hz power, particularly during periods of low 
locomotor activity (F; ***p < 0.001 by linear regression analysis and slope test) but did not 
significantly change the tight relationship between EDs and low-frequency oscillations (G).
Values are expressed as mean ± SEM (A–E) or 95% CI (F and G). See also Figure S5.
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Figure 7. Chronic GNE-0723 Treatment Improves Cognitive Functions in J20 and Scn1a-KI 
Mice
Sex-mixed 7- to 11-month-old J20 and 10- to 12-month-old Scn1a-KI mice and their 
respective littermate WT controls were treated with 3 mg/kg GNE-0723 or vehicle every 48 
h for at least 2 weeks before assessing cognitive performance (for J20, n = 9–13 WT and 15–
16 J20 mice per treatment group; for Scn1a-KI, n = 12–14 WT and 12–15 Scn1a-KI mice 
per treatment group).
(A) Escape distance during the hidden platform training of the water maze test with standard 
(196 cm2) and small (100 cm2) platforms.
(B) Water maze 24-h probe trials after 3 (left) and 5 (right) days of hidden platform training 
with a standard platform. GEN-0723-treated, but not vehicle-treated, J20 mice had quadrant 
preference after 3 days of hidden platform training (left), indicating that GEN-0723 
enhances spatial memory. **p < 0.01; ***p < 0.001 versus non-target quadrant locations by 
paired two-tailed Student’s t test.
(C) 24- and 196-h probe trials after 8 days of hidden platform training in the water maze. 
GEN-0723-treated J20 and WT mice had stronger quadrant preference during the 196-h 
probe trial (right), indicating that GEN-0723 enhances long-term spatial memory. *p < 0.05; 
***p < 0.001 versus non-target quadrant locations by paired two-tailed Student’s t test.
(D) Percentage time freezing in the fear conditional test. Scn1a-KI mice had impaired fear 
learning during the training (left), 24-h recall in the same environment (middle), and 48-h 
recall in a similar environment (right). Compared to vehicle-treated Scn1a-KI mice, 
GEN-0723 treatment enhanced performance during the training and 48-h recall in Scn1a-KI 
mice. **p < 0.01; ***p < 0.001 by repeated-measures ANOVA and Bonferroni post hoc test.
Values are expressed as mean ± SEM. See also Figure S6.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Chemicals, Peptides, and Recombinant Proteins
(+)-MK-801 Tocris Tocris Cat. # 0924
(−)-MK-801 Tocris Tocris Cat. # 0955
GNE-0723 Pharmaron, Inc. according to methods provided in 
Volgraf et al., 2016
GNE-0723
Methylcellulose Sigma Aldrich M6385 Lot #SLBN3595V
Tween 80 Sigma Aldrich P4780 Lot #MKBS8228V
Experimental Models: Cell Lines
Hamster: CHO GluN1/GluN2A cells Genentech, as described in Hackos et al., 2016 N/A
Experimental Models: Organisms/Strains
Mouse: B6.Cg-Tg(PDGFB-APPSwInd) 20Lms/
2Mmjax
Gladstone Institute of Neurological Disease Jax stock # 34836-JAX
Mouse: Scn1aR1407X/+ Ogiwara et al., 2007 N/A
Mouse: FVB/NJ Jackson Laboratory Jax Stock #001800
Mouse: C57BL/6J Jackson Laboratory Jax Stock #000664
Mouse: tdTomato reporter Jackson Laboratory Jax Stock #007914
Mouse: Parvalbumin (PV)-cre Jackson Laboratory Jax Stock #008069
Mouse: GluN2AKO Kadotani et al., 1996 N/A
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